Home The Word Brain	My Amedeo FAQ Privacy About
	2049 Chinese The 20K Word Road to Mandarin Proficiency By B. S. Kamps et al.

Schizophrenia

Free Subscription Articles published in Am J Psychiatry Retrieve available abstracts of 86 articles: HTML format

Single Articles

December 2024
1. HORAN WP, Sauder C, Harvey PD, Ramsay IS, et al
   The Impact of Xanomeline and Trospium Chloride on Cognitive Impairment in Acute Schizophrenia: Replication in Pooled Data From Two Phase 3 Trials.
   Am J Psychiatry. 2024 Dec 11. doi: 10.1176/appi.ajp.20240076.
   PubMed     Abstract available
   
   
   October 2024
2. GALLUCCI J, Yu JC, Oliver LD, Nakua H, et al
   Neural Circuitry and Therapeutic Targeting of Depressive Symptoms in Schizophrenia Spectrum Disorders.
   Am J Psychiatry. 2024;181:910-919.
   PubMed     Abstract available
   
   
   
3. REILLY TJ, McCutcheon RA
   Menopausal Hormone Therapy for Women With Schizophrenia: What's Stopping Us?
   Am J Psychiatry. 2024;181:854-855.
   PubMed    
   
   
   
4. KRAMER EN, Velicu V
   Aripiprazole Augmentation as a Treatment for Clozapine-Induced Weight Gain.
   Am J Psychiatry. 2024;181:935-936.
   PubMed    
   
   
   
5. CHENGAPPA KNR, Cotes RO
   Clozapine's High Incidence of Ileus and Pneumonia Demand Better Clinical Strategies-How Do We Get There?
   Am J Psychiatry. 2024;181:851-853.
   PubMed    
   
   
   
6. MCINTYRE RS, Kwan ATH, Rosenblat JD, Teopiz KM, et al
   Aripiprazole Augmentation as a Treatment for Clozapine-Induced Weight Gain: Response to Kramer and Velicu.
   Am J Psychiatry. 2024;181:936-937.
   PubMed    
   
   
   
7. HWANG M, Brady R
   Neural Circuitry and Therapeutic Targeting of Depressive Symptoms in Schizophrenia Spectrum Disorders.
   Am J Psychiatry. 2024;181:858-860.
   PubMed    
   
   
   
8. ARNSTEN AFT, Datta D
   Characterizing the Most Vulnerable Prefrontal Cortical Neurons in Schizophrenia.
   Am J Psychiatry. 2024;181:861-864.
   PubMed    
   
   
   
9. TAMMINGA CA
   Psychosis Risk With Prescription Amphetamine.
   Am J Psychiatry. 2024;181:856-857.
   PubMed    
   
   
   
10. KALIN NH
    Schizophrenia Spectrum Disorders and Psychosis.
    Am J Psychiatry. 2024;181:847-850.
    PubMed    
    
    
    
11. LEUCHT S, Priller J, Davis JM
    Antipsychotic Drugs: A Concise Review of History, Classification, Indications, Mechanism, Efficacy, Side Effects, Dosing, and Clinical Application.
    Am J Psychiatry. 2024;181:865-878.
    PubMed     Abstract available
    
    
    
12. ARION D, Enwright JF 3rd, Gonzalez-Burgos G, Lewis DA, et al
    Cell Type-Specific Profiles and Developmental Trajectories of Transcriptomes in Primate Prefrontal Layer 3 Pyramidal Neurons: Implications for Schizophrenia.
    Am J Psychiatry. 2024;181:920-934.
    PubMed     Abstract available
    
    
    September 2024
13. PARTANEN JJ, Happola P, Kampe A, Ahola-Olli A, et al
    High Burden of Ileus and Pneumonia in Clozapine-Treated Individuals With Schizophrenia: A Finnish 25-Year Follow-Up Register Study.
    Am J Psychiatry. 2024 Sep 12:appiajp20230744. doi: 10.1176/appi.ajp.20230744.
    PubMed     Abstract available
    
    
    
14. MORAN LV, Skinner JP, Shinn AK, Nielsen K, et al
    Risk of Incident Psychosis and Mania With Prescription Amphetamines.
    Am J Psychiatry. 2024 Sep 12:appiajp20230329. doi: 10.1176/appi.ajp.20230329.
    PubMed     Abstract available
    
    
    
15. BRAND BA, Sommer IE, Gangadin SS, Tanskanen A, et al
    Real-World Effectiveness of Menopausal Hormone Therapy in Preventing Relapse in Women With Schizophrenia or Schizoaffective Disorder.
    Am J Psychiatry. 2024 Sep 12:appiajp20230850. doi: 10.1176/appi.ajp.20230850.
    PubMed     Abstract available
    
    
    July 2024
16. JONSSON L, Horbeck E, Primerano A, Song J, et al
    Association of Occupational Dysfunction and Hospital Admissions With Different Polygenic Profiles in Bipolar Disorder.
    Am J Psychiatry. 2024;181:620-629.
    PubMed     Abstract available
    
    
    June 2024
17. KURTZ MM
    Cognitive Remediation in Schizophrenia Spectrum Illness: Evidence for Treatment Persistence.
    Am J Psychiatry. 2024;181:471-473.
    PubMed    
    
    
    
18. VANO LJ, Veronese M, McCutcheon RA, Howes OD, et al
    Neuromelanin-Sensitive MRI: A Biomarker for Treatment-Resistant Schizophrenia?
    Am J Psychiatry. 2024;181:468-470.
    PubMed    
    
    
    
19. BRENNAND KJ
    Aligning Stem Cell Models and Postmortem Studies to Query Striatal Neurodevelopment in Schizophrenia.
    Am J Psychiatry. 2024;181:465-467.
    PubMed    
    
    
    
20. BIRNBAUM R, Weinberger DR
    The Genesis of Schizophrenia: An Origin Story.
    Am J Psychiatry. 2024;181:482-492.
    PubMed     Abstract available
    
    
    
21. KALIN NH
    Advances in Understanding Schizophrenia, ADHD, and ASD.
    Am J Psychiatry. 2024;181:461-464.
    PubMed    
    
    
    
22. TRAMAZZO S, Lian W, Ajnakina O, Carlson G, et al
    Long-Term Course of Remission and Recovery in Psychotic Disorders.
    Am J Psychiatry. 2024;181:532-540.
    PubMed     Abstract available
    
    
    May 2024
23. KANG J, Castro VM, Ripperger M, Venkatesh S, et al
    Genome-Wide Association Study of Treatment-Resistant Depression: Shared Biology With Metabolic Traits.
    Am J Psychiatry. 2024 May 15:appiajp20230247. doi: 10.1176/appi.ajp.20230247.
    PubMed     Abstract available
    
    
    April 2024
24. LIGHT GA, Swerdlow NR
    Predicting Conversion to Psychosis: What Lies Beyond the Biomarkers?
    Am J Psychiatry. 2024;181:272-274.
    PubMed    
    
    
    March 2024
25. VAN DER PLUIJM M, Wengler K, Reijers PN, Cassidy CM, et al
    Neuromelanin-Sensitive MRI as Candidate Marker for Treatment Resistance in First-Episode Schizophrenia.
    Am J Psychiatry. 2024 Mar 13:appiajp20220780. doi: 10.1176/appi.ajp.20220780.
    PubMed     Abstract available
    
    
    
26. VITA A, Barlati S, Ceraso A, Nibbio G, et al
    Durability of Effects of Cognitive Remediation on Cognition and Psychosocial Functioning in Schizophrenia: A Systematic Review and Meta-Analysis of Randomized Clinical Trials.
    Am J Psychiatry. 2024 Mar 13:appiajp20230396. doi: 10.1176/appi.ajp.20230396.
    PubMed     Abstract available
    
    
    February 2024
27. HOU Y, Xia H, He T, Zhang B, et al
    N2 Responses in Youths With Psychosis Risk Syndrome and Their Association With Clinical Outcomes: A Cohort Follow-Up Study Based on the Three-Stimulus Visual Oddball Paradigm.
    Am J Psychiatry. 2024 Feb 29:appiajp20221013. doi: 10.1176/appi.ajp.20221013.
    PubMed     Abstract available
    
    
    
28. ROGNLI EB, Hoye A, Bramness JG
    Methamphetamine-Induced Psychosis and Schizophrenia: A Call for Special Attention: Response to Zhu et al.
    Am J Psychiatry. 2024;181:168-169.
    PubMed    
    
    
    
29. ZHU L, Ni T, Guan F
    Methamphetamine-Induced Psychosis and Schizophrenia: A Call for Special Attention.
    Am J Psychiatry. 2024;181:168.
    PubMed    
    
    
    November 2023
30. SAWADA T, Barbosa AR, Araujo B, McCord AE, et al
    Recapitulation of Perturbed Striatal Gene Expression Dynamics of Donor's Brains With Ventral Forebrain Organoids Derived From the Same Individuals With Schizophrenia.
    Am J Psychiatry. 2023 Nov 2:appiajp20220723. doi: 10.1176/appi.ajp.20220723.
    PubMed     Abstract available
    
    
    
31. KALIN NH
    New Insights Into Psychotic Disorders.
    Am J Psychiatry. 2023;180:779-781.
    PubMed    
    
    
    
32. VAN DER VEN E, Susser E
    Structural Racism and Risk of Schizophrenia.
    Am J Psychiatry. 2023;180:782-784.
    PubMed    
    
    
    
33. CANNON TD
    Predicting Conversion to Psychosis Using Machine Learning: Are We There Yet?
    Am J Psychiatry. 2023;180:789-791.
    PubMed    
    
    
    
34. GOFF DC, Roffman J, Holt DJ
    Another Step Toward the Prediction of Antipsychotic Treatment Response Using Functional Connectivity.
    Am J Psychiatry. 2023;180:787-788.
    PubMed    
    
    
    
35. FORSYTH JK, Bearden CE
    Rethinking the First Episode of Schizophrenia: Identifying Convergent Mechanisms During Development and Moving Toward Prediction.
    Am J Psychiatry. 2023;180:792-804.
    PubMed    
    
    
    
36. STRAWBRIDGE RJ, Graham N
    Dissecting the Genetic Relationship Between Schizophrenia and Cardiovascular Disease.
    Am J Psychiatry. 2023;180:785-786.
    PubMed    
    
    
    
37. JOSHI Y, Swerdlow N, Light G
    Points that Need Attention in Early Auditory Information Processing Research in Schizophrenia: Response to Lin and Hsieh.
    Am J Psychiatry. 2023;180:841-842.
    PubMed    
    
    
    October 2023
38. SMUCNY J, Davidson I, Carter CS
    Are We There Yet? Predicting Conversion to Psychosis Using Machine Learning.
    Am J Psychiatry. 2023 Oct 4:appiajp20220973. doi: 10.1176/appi.ajp.20220973.
    PubMed    
    
    
    September 2023
39. RODEVAND L, Rahman Z, Hindley GFL, Smeland OB, et al
    Characterizing the Shared Genetic Underpinnings of Schizophrenia and Cardiovascular Disease Risk Factors.
    Am J Psychiatry. 2023 Sep 27:appiajp20220660. doi: 10.1176/appi.ajp.20220660.
    PubMed     Abstract available
    
    
    
40. KUMAR K, Modenato C, Moreau C, Ching CRK, et al
    Subcortical Brain Alterations in Carriers of Genomic Copy Number Variants.
    Am J Psychiatry. 2023;180:685-698.
    PubMed     Abstract available
    
    
    August 2023
41. CAO H, Lencz T, Gallego JA, Rubio JM, et al
    A Functional Connectome-Based Neural Signature for Individualized Prediction of Antipsychotic Response in First-Episode Psychosis.
    Am J Psychiatry. 2023 Aug 30:appiajp20220719. doi: 10.1176/appi.ajp.20220719.
    PubMed     Abstract available
    
    
    June 2023
42. VASSOS E
    What is the Link Between Substance-Induced Psychosis and Primary Psychotic Disorders?
    Am J Psychiatry. 2023;180:404-406.
    PubMed    
    
    
    May 2023
43. ROGNLI EB, Heiberg IH, Jacobsen BK, Hoye A, et al
    Transition From Substance-Induced Psychosis to Schizophrenia Spectrum Disorder or Bipolar Disorder.
    Am J Psychiatry. 2023 May 3:appiajp22010076. doi: 10.1176/appi.ajp.22010076.
    PubMed     Abstract available
    
    
    
44. KALIN NH
    Treatment Issues Related to the Use of Psychedelics, Trichotillomania, Social Anxiety Disorder, Schizophrenia, and Opioid Use Disorder.
    Am J Psychiatry. 2023;180:321-324.
    PubMed    
    
    
    
45. VINOGRADOV S, Meyer-Kalos P
    Treating Pathologies of the Will.
    Am J Psychiatry. 2023;180:331-333.
    PubMed    
    
    
    
46. BUCHANAN RW, Kreyenbuhl J
    An Argument for Antipsychotic Polypharmacy.
    Am J Psychiatry. 2023;180:334-336.
    PubMed    
    
    
    April 2023
47. DIENEL SJ, Fish KN, Lewis DA
    The Nature of Prefrontal Cortical GABA Neuron Alterations in Schizophrenia: Markedly Lower Somatostatin and Parvalbumin Gene Expression Without Missing Neurons.
    Am J Psychiatry. 2023 Apr 19:appiajp20220676. doi: 10.1176/appi.ajp.20220676.
    PubMed     Abstract available
    
    
    
48. JOSHI YB, Molina JL, Braff DL, Green MF, et al
    Sensitivity of Schizophrenia Endophenotype Biomarkers to Anticholinergic Medication Burden.
    Am J Psychiatry. 2023 Apr 11:appiajp20220649. doi: 10.1176/appi.ajp.20220649.
    PubMed    
    
    
    
49. ZWICKER A, Fullerton JM, Mullins N, Rice F, et al
    Polygenic Scores and Onset of Major Mood or Psychotic Disorders Among Offspring of Affected Parents.
    Am J Psychiatry. 2023;180:285-293.
    PubMed     Abstract available
    
    
    March 2023
50. TAIPALE H, Tanskanen A, Tiihonen J
    Safety of Antipsychotic Polypharmacy Versus Monotherapy in a Nationwide Cohort of 61,889 Patients With Schizophrenia.
    Am J Psychiatry. 2023 Mar 22:appiajp20220446. doi: 10.1176/appi.ajp.20220446.
    PubMed     Abstract available
    
    
    
51. REDDY LF, Glynn SM, McGovern JE, Sugar CA, et al
    A Novel Psychosocial Intervention for Motivational Negative Symptoms in Schizophrenia: Combined Motivational Interviewing and CBT.
    Am J Psychiatry. 2023 Mar 9:appiajp20220243. doi: 10.1176/appi.ajp.20220243.
    PubMed     Abstract available
    
    
    
52. HASSERIS S, Albinana C, Vilhjalmsson BJ, Mortensen PB, et al
    Polygenic Risk and Episode Polarity Among Individuals With Bipolar Disorder.
    Am J Psychiatry. 2023;180:200-208.
    PubMed     Abstract available
    
    
    January 2023
53. BANERJEE D, Girirajan S
    Pathogenic Variants and Ascertainment: Neuropsychiatric Disease Risk in a Health System Cohort.
    Am J Psychiatry. 2023;180:11-13.
    PubMed    
    
    
    
54. SHIMELIS H, Oetjens MT, Walsh LK, Wain KE, et al
    Prevalence and Penetrance of Rare Pathogenic Variants in Neurodevelopmental Psychiatric Genes in a Health Care System Population.
    Am J Psychiatry. 2023;180:65-72.
    PubMed     Abstract available
    
    
    December 2022
55. BARBER G, Nemeroff CB, Siegel S
    A Case of Prolonged Mania, Psychosis, and Severe Depression After Psilocybin Use: Implications of Increased Psychedelic Drug Availability.
    Am J Psychiatry. 2022;179:892-896.
    PubMed    
    
    
    November 2022
56. JONAS KG, Fochtmann LJ, Perlman G, Kane JM, et al
    Distinguishing the Effects of Lead-Time Bias and Duration of Untreated Psychosis.
    Am J Psychiatry. 2022;179:862-863.
    PubMed    
    
    
    
57. SKUSE DH
    Early-Onset Psychosis and Autism Spectrum Disorder: Similar Rates of Deleterious Copy Number Variants, Yet Diverse Phenotypic Manifestations.
    Am J Psychiatry. 2022;179:798-799.
    PubMed    
    
    
    
58. KALIN NH
    Polygenic Risk Scores and Genetics in Psychiatry.
    Am J Psychiatry. 2022;179:781-784.
    PubMed    
    
    
    
59. O'KEEFFE D, Kinsella A, Waddington JL, Clarke M, et al
    Distinguishing the Effects of Lead-Time Bias and Duration of Untreated Psychosis: Reply to Jonas et al.
    Am J Psychiatry. 2022;179:863-864.
    PubMed    
    
    
    
60. SIGSTROM R, Kowalec K, Jonsson L, Clements CC, et al
    Association Between Polygenic Risk Scores and Outcome of ECT.
    Am J Psychiatry. 2022;179:844-852.
    PubMed     Abstract available
    
    
    October 2022
61. SOLMI M, Taipale H, Holm M, Tanskanen A, et al
    Effectiveness of Antipsychotic Use for Reducing Risk of Work Disability: Results From a Within-Subject Analysis of a Swedish National Cohort of 21,551 Patients With First-Episode Nonaffective Psychosis.
    Am J Psychiatry. 2022 Oct 6:appiajp21121189. doi: 10.1176/appi.ajp.21121189.
    PubMed     Abstract available
    
    
    September 2022
62. GREGERSEN M, Mollegaard Jepsen JR, Rohd SB, Sondergaard A, et al
    Developmental Pathways and Clinical Outcomes of Early Childhood Psychotic Experiences in Preadolescent Children at Familial High Risk of Schizophrenia or Bipolar Disorder: A Prospective, Longitudinal Cohort Study - The Danish High Risk and Resilience
    Am J Psychiatry. 2022;179:628-639.
    PubMed     Abstract available
    
    
    
63. COTTER D, Healy C, Staines L, Mongan D, et al
    Broadening the Parameters of Clinical High Risk for Psychosis.
    Am J Psychiatry. 2022;179:593-595.
    PubMed    
    
    
    August 2022
64. BROWNSTEIN CA, Douard E, Mollon J, Smith R, et al
    Similar Rates of Deleterious Copy Number Variants in Early-Onset Psychosis and Autism Spectrum Disorder.
    Am J Psychiatry. 2022 Aug 24:appiajp21111175. doi: 10.1176/appi.ajp.21111175.
    PubMed     Abstract available
    
    
    June 2022
65. PAUL SM, Yohn SE, Popiolek M, Miller AC, et al
    Muscarinic Acetylcholine Receptor Agonists as Novel Treatments for Schizophrenia.
    Am J Psychiatry. 2022 Jun 27:appiajp21101083. doi: 10.1176/appi.ajp.21101083.
    PubMed     Abstract available
    
    
    April 2022
66. CHAND GB, Singhal P, Dwyer DB, Wen J, et al
    Schizophrenia Imaging Signatures and Their Associations With Cognition, Psychopathology, and Genetics in the General Population.
    Am J Psychiatry. 2022 Apr 12:appiajp21070686. doi: 10.1176/appi.ajp.21070686.
    PubMed     Abstract available
    
    
    
67. O'KEEFFE D, Kinsella A, Waddington JL, Clarke M, et al
    20-Year Prospective, Sequential Follow-Up Study of Heterogeneity in Associations of Duration of Untreated Psychosis With Symptoms, Functioning, and Quality of Life Following First-Episode Psychosis.
    Am J Psychiatry. 2022;179:288-297.
    PubMed     Abstract available
    
    
    
68. CHUNG DW, Geramita MA, Lewis DA
    Synaptic Variability and Cortical Gamma Oscillation Power in Schizophrenia.
    Am J Psychiatry. 2022;179:277-287.
    PubMed     Abstract available
    
    
    
69. KALIN NH
    Integrating Clinical and Basic Research: Opioid Use Disorder, Psychotic Illnesses, and Prefrontal Microcircuits Relevant to Schizophrenia.
    Am J Psychiatry. 2022;179:255-258.
    PubMed    
    
    
    
70. MALLA A
    Reducing Duration of Untreated Psychosis: The Neglected Dimension of Early Intervention Services.
    Am J Psychiatry. 2022;179:259-261.
    PubMed    
    
    
    
71. SOHAL VS
    Transforming Discoveries About Cortical Microcircuits and Gamma Oscillations Into New Treatments for Cognitive Deficits in Schizophrenia.
    Am J Psychiatry. 2022;179:267-276.
    PubMed     Abstract available
    
    
    March 2022
72. MANCINI V, Rochas V, Seeber M, Roehri N, et al
    Aberrant Developmental Patterns of Gamma-Band Response and Long-Range Communication Disruption in Youths With 22q11.2 Deletion Syndrome.
    Am J Psychiatry. 2022;179:204-215.
    PubMed     Abstract available
    
    
    January 2022
73. GANESH S, D'Souza DC
    Cannabis and Psychosis: Recent Epidemiological Findings Continuing the "Causality Debate".
    Am J Psychiatry. 2022;179:8-10.
    PubMed    
    
    
    
74. SANCHEZ-RICO M, Limosin F, Hoertel N
    Is a Diagnosis of Schizophrenia Spectrum Disorder Associated With Increased Mortality in Patients With COVID-19?
    Am J Psychiatry. 2022;179:71-73.
    PubMed    
    
    
    October 2021
75. KALIN NH
    Depression and Schizophrenia: Sleep, Medical Risk Factors, Biomarkers, and Treatment.
    Am J Psychiatry. 2021;178:881-884.
    PubMed    
    
    
    
76. CANNON TD
    Do the Benefits of Early Intervention Services for Psychosis Generalize and Persist in the Real World?
    Am J Psychiatry. 2021;178:890-892.
    PubMed    
    
    
    September 2021
77. KALIN NH
    Insights Into Improving Clinical Outcomes Across Psychiatric Disorders and Medical Comorbidities.
    Am J Psychiatry. 2021;178:779-782.
    PubMed    
    
    
    August 2021
78. PARKER DA, Trotti RL, McDowell JE, Keedy SK, et al
    Auditory Oddball Responses Across the Schizophrenia-Bipolar Spectrum and Their Relationship to Cognitive and Clinical Features.
    Am J Psychiatry. 2021 Aug 19:appiajp202120071043.
    PubMed     Abstract available
    
    
    July 2021
79. POSSELT CM, Albert N, Nordentoft M, Hjorthoj C, et al
    The Danish OPUS Early Intervention Services for First-Episode Psychosis: A Phase 4 Prospective Cohort Study With Comparison of Randomized Trial and Real-World Data.
    Am J Psychiatry. 2021 Jul 28:appiajp202120111596.
    PubMed     Abstract available
    
    
    
80. WEISER M, Davis JM, Brown CH, Slade EP, et al
    Differences in Antipsychotic Treatment Discontinuation Among Veterans With Schizophrenia in the U.S. Department of Veterans Affairs.
    Am J Psychiatry. 2021 Jul 14:appiajp202020111657.
    PubMed     Abstract available
    
    
    
81. MARDER SR
    Changing the Face of Schizophrenia.
    Am J Psychiatry. 2021;178:584-585.
    PubMed    
    
    
    May 2021
82. JOSHI YB, Thomas ML, Braff DL, Green MF, et al
    Anticholinergic Medication Burden-Associated Cognitive Impairment in Schizophrenia.
    Am J Psychiatry. 2021 May 14:appiajp202020081212.
    PubMed     Abstract available
    
    
    
83. ANGLIN DM, Ereshefsky S, Klaunig MJ, Bridgwater MA, et al
    From Womb to Neighborhood: A Racial Analysis of Social Determinants of Psychosis in the United States.
    Am J Psychiatry. 2021 May 3:appiajp202020071091.
    PubMed     Abstract available
    
    
    
84. HONER WG
    Better Evidence for Pharmacological Maintenance Treatment in Nonaffective Psychoses: Implications for Relapse Prevention.
    Am J Psychiatry. 2021;178:369-371.
    PubMed    
    
    
    
85. FERRARELLI F, Phillips ML
    Examining and Modulating Neural Circuits in Psychiatric Disorders With Transcranial Magnetic Stimulation and Electroencephalography: Present Practices and Future Developments.
    Am J Psychiatry. 2021;178:400-413.
    PubMed     Abstract available
    
    
    April 2021
86. AMSALEM D, Markowitz JC, Jankowski SE, Yang LH, et al
    Sustained Effect of a Brief Video in Reducing Public Stigma Toward Individuals With Psychosis: A Randomized Controlled Trial of Young Adults.
    Am J Psychiatry. 2021 Apr 26:appiajp202020091293.
    PubMed     Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Schizophrenia is free of charge.